Nonalcoholic Steatohepatitis

To the Editor: In the review article by Diehl and Day (Nov. 23 issue), 1 about the cause, pathogenesis, and treatment of nonalcoholic steatohepatitis, the authors did not mention liraglutide (a glucagon-like peptide 1 analogue) as a therapy in Table 2. Armstrong et al. 2 describe a phase 2 study of the safety and efficacy of liraglutide in patients with nonalcoholic steatohepatitis. A total of 26 patients were randomly assigned to receive liraglutide and 26 to receive placebo. Complete resolution of nonalcoholic steatohepatitis (as assessed on liver biopsy) was observed in 39% of the patients in the liraglutide group, as compared with . . .